Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming

Hepatocellular carcinomas (HCC) exhibit distinct promoter hypermethylation patterns, but the epigenetic regulation and function of transcriptional enhancers remain unclear. Here, our affinity- and bisulfite-based whole-genome sequencing analyses reveal global enhancer hypomethylation in human HCCs. Integrative epigenomic characterization further pinpoints a recurrent hypomethylated enhancer of CCAAT/enhancer-binding protein-beta (C/EBPβ) which correlates with C/EBPβ over-expression and poorer prognosis of patients. Demethylation of C/EBPβ enhancer reactivates a self-reinforcing enhancer-target loop via direct transcriptional up-regulation of enhancer RNA. Conversely, deletion of this enhancer via CRISPR/Cas9 reduces C/EBPβ expression and its genome-wide co-occupancy with BRD4 at H3K27ac-marked enhancers and super-enhancers, leading to drastic suppression of driver oncogenes and HCC tumorigenicity. Hepatitis B X protein transgenic mouse model of HCC recapitulates this paradigm, as C/ebpβ enhancer hypomethylation associates with oncogenic activation in early tumorigenesis. These results support a causal link between aberrant enhancer hypomethylation and C/EBPβ over-expression, thereby contributing to hepatocarcinogenesis through global transcriptional reprogramming.There are distinct hypermethylation patterns in gene promoters in hepatocellular carcinomas (HCCs). Here, the authors show that the enhancer of C/EBPβ is recurrently hypomethylated in human HCCs, recapitulating this in a transgenic murine model and linking aberrant enhancer hypomethylation to hepatocarcinogenesis.

[1]  Martin J. Aryee,et al.  Coverage recommendations for methylation analysis by whole genome bisulfite sequencing , 2014, Nature Methods.

[2]  J. Llovet,et al.  Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning , 2014, Nature Reviews Clinical Oncology.

[3]  D. Theodorescu,et al.  RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer , 2018, Pharmacological Reviews.

[4]  Jingde Zhu,et al.  Hepatitis virus infection affects DNA methylation in mice with humanized livers. , 2014, Gastroenterology.

[5]  A. Cheng,et al.  Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. , 2013, Seminars in cancer biology.

[6]  Erik Splinter,et al.  The complex transcription regulatory landscape of our genome: control in three dimensions , 2011, The EMBO journal.

[7]  Kuen-Feng Chen,et al.  Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. , 2015, Journal of the National Cancer Institute.

[8]  J. Massagué,et al.  C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. , 2006, Cancer cell.

[9]  Helene Kretzmer,et al.  metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data , 2016, Genome research.

[10]  J. Wysocka,et al.  Modification of enhancer chromatin: what, how, and why? , 2013, Molecular cell.

[11]  Nathaniel D. Heintzman,et al.  Histone modifications at human enhancers reflect global cell-type-specific gene expression , 2009, Nature.

[12]  Richard M Myers,et al.  Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/ enhancer-binding protein beta binding sites , 2015, Genome research.

[13]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[14]  C. Glass,et al.  Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation , 2013, Nature.

[15]  Y. Maehara,et al.  The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma , 2010, Oncology.

[16]  G. Gores,et al.  Hepatocellular carcinoma , 2016, Nature Reviews Disease Primers.

[17]  Jun Yu,et al.  Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis , 2014, Gut.

[18]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[19]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[20]  N. Wong,et al.  Genomic aberrations in human hepatocellular carcinomas of differing etiologies. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[22]  Keith A. Boroevich,et al.  Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.

[23]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[24]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[25]  Anne Song,et al.  Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling , 2017, Nature.

[26]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[27]  S. Jang,et al.  Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity , 2015, Molecular Cancer Therapeutics.

[28]  U. Schibler,et al.  A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the sam mRNA , 1991, Cell.

[29]  Jun S. Song,et al.  Intratumoral Heterogeneity of the Epigenome. , 2016, Cancer cell.

[30]  S. Murakami,et al.  Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. , 1999, Journal of hepatology.

[31]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[32]  A. Coulibaly,et al.  An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells , 2016, Leukemia.

[33]  R. Shamir,et al.  Enhancer methylation dynamics contribute to cancer plasticity and patient mortality , 2016, Genome research.

[34]  Eric Nestler,et al.  ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases , 2014, BMC Genomics.

[35]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[36]  Swe Swe Myint,et al.  VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. , 2017, Cancer discovery.

[37]  Ralf Herwig,et al.  MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments , 2013, Bioinform..

[38]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[39]  Charles Y. Lin,et al.  Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer , 2016, Genome Biology.

[40]  Kevin Y. Yip,et al.  Reconstruction of enhancer–target networks in 935 samples of human primary cells, tissues and cell lines , 2017, Nature Genetics.

[41]  Tao Luo,et al.  PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression , 2016, Autophagy.

[42]  P. Kantoff,et al.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation , 2014, Proceedings of the National Academy of Sciences.

[43]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[44]  G. Natoli,et al.  Noncoding transcription at enhancers: general principles and functional models. , 2012, Annual review of genetics.

[45]  Maureen A. Sartor,et al.  annotatr: Genomic regions in context , 2016, bioRxiv.

[46]  S. Thorgeirsson,et al.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. , 2007, The Journal of clinical investigation.

[47]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[48]  Wei Li,et al.  DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. , 2016, Cancer cell.

[49]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[50]  Kenichiro Hata,et al.  Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions , 2016, Nature Biotechnology.

[51]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[52]  Zhou Zhu,et al.  Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma , 2013, Hepatology.

[53]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[54]  D. Reinberg,et al.  BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones , 2014, Nature Structural &Molecular Biology.

[55]  T. Golub,et al.  Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells , 2004, Cancer Research.

[56]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[57]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[58]  S. Knapp,et al.  BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire , 2016, Nucleic acids research.

[59]  Jun Yu,et al.  Yin Yang 1‐mediated epigenetic silencing of tumour‐suppressive microRNAs activates nuclear factor‐κB in hepatocellular carcinoma , 2016, The Journal of pathology.

[60]  Yonatan Stelzer,et al.  Editing DNA Methylation in the Mammalian Genome , 2016, Cell.

[61]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[62]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[63]  J. T. Erichsen,et al.  Enhancer Evolution across 20 Mammalian Species , 2015, Cell.

[64]  Gwendolyn M. Jang,et al.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.

[65]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[66]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[67]  L. Gravitz.  Liver cancer , 2014, Nature.

[68]  Sivan Sabato,et al.  DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes , 2013, Genome Biology.

[69]  Alejandro Marambio-Tapia,et al.  Off , 2020, Definitions.

[70]  Y. C. Long,et al.  Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells , 2016, Hepatology.

[71]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[72]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[73]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[74]  Sandya Liyanarachchi,et al.  Molecular and Cellular Pathobiology Epigenetic Silencing Mediated through Activated PI 3 K / AKT Signaling in Breast Cancer , 2011 .

[75]  A. Frigessi,et al.  DNA methylation at enhancers identifies distinct breast cancer lineages , 2017, Nature Communications.

[76]  Roger R. Gomis,et al.  C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells , 2006 .

[77]  I. Goldstein,et al.  Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response. , 2017, Genome research.

[78]  R. Elkon,et al.  eRNAs are required for p53-dependent enhancer activity and gene transcription. , 2013, Molecular cell.

[79]  Hsuan-Cheng Huang,et al.  Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway , 2010, Gut.

[80]  D. Nguyen,et al.  Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. , 2013, Cancer cell.

[81]  W. Guo,et al.  Genome‐wide copy number analyses identified novel cancer genes in hepatocellular carcinoma , 2011, Hepatology.

[82]  S. Murphy,et al.  Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[83]  M. Szyf,et al.  Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets , 2014, Clinical Cancer Research.

[84]  Young-Joon Kim,et al.  HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators , 2014, Proceedings of the National Academy of Sciences.

[85]  B. Porse,et al.  Temporal mapping of CEBPA and CEBPB binding during liver regeneration reveals dynamic occupancy and specific regulatory codes for homeostatic and cell cycle gene batteries , 2013, Genome research.

[86]  D. Sabatini,et al.  A CRISPR screen identifies a pathway required for paraquat-induced cell death , 2017, Nature chemical biology.

[87]  Neva C. Durand,et al.  A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping , 2014, Cell.

[88]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[89]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[90]  J. L. Mateo,et al.  CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool , 2015, PloS one.